Australia's most trusted
source of pharma news
Saturday, 22 February 2025
Posted 19 February 2025 AM
Just over half of the current-top valued investigational drug candidates in Evaluate’s latest industry forecast are owned by pharmaceutical companies with a presence in Australia, hinting at upcoming regulatory filings and potential market rivalries in the coming years.
The updated list ranks the leading 10 R&D programs by net present value (NPV) with the top four positions now occupied by novel anti-obesity/type 2 diabetes agents.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.